Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2014, Article ID 385120, 17 pages
http://dx.doi.org/10.1155/2014/385120
Research Article

Design of Glucagon-Like Peptide-1 Receptor Agonist for Diabetes Mellitus from Traditional Chinese Medicine

1Department of Biomedical Informatics, Asia University, Taichung 41354, Taiwan
2Department of Medicine, China Medical University, Taichung 40402, Taiwan

Received 15 January 2014; Accepted 29 January 2014; Published 6 May 2014

Academic Editor: Fuu-Jen Tsai

Copyright © 2014 Hsin-Chieh Tang and Calvin Yu-Chian Chen. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. B. Finan, T. Ma, N. Ottaway et al., “Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans,” Science Translational Medicine, vol. 5, no. 209, Article ID 209ra151, 2013. View at Publisher · View at Google Scholar
  2. P. J. Randle, P. B. Garland, C. N. Hales, and E. A. Newsholme, “The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus,” The Lancet, vol. 281, no. 7285, pp. 785–789, 1963. View at Google Scholar · View at Scopus
  3. H. Y. Sun, F. D. Ke, and J. S. Wen, “Prevalence of diabetes among men and women in China,” The New England Journal of Medicine, vol. 362, no. 25, pp. 2425–2426, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. J. Nerup, P. Platz, and O. Ortved Andersen, “HL A antigens and diabetes mellitus,” The Lancet, vol. 2, no. 7885, pp. 864–866, 1974. View at Google Scholar · View at Scopus
  5. G. F. Bottazzo, A. Florin Christensen, and D. Doniach, “Islet cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies,” The Lancet, vol. 2, no. 7892, pp. 1279–1283, 1974. View at Google Scholar · View at Scopus
  6. J. A. Todd, J. I. Bell, and H. O. McDevitt, “HLA-DQ(β) gene contributes to susceptibility and resistance to insulin-dependent diabetes mellitus,” Nature, vol. 329, no. 6140, pp. 599–604, 1987. View at Google Scholar · View at Scopus
  7. P. Concannon, K. J. Gogolin-Ewens, D. A. Hinds et al., “A second-generation screen of the human genome for susceptibility to insulin-dependent diabetes mellitus,” Nature Genetics, vol. 19, no. 3, pp. 292–296, 1998. View at Publisher · View at Google Scholar · View at Scopus
  8. G. I. Bell and K. S. Polonsky, “Diabetes mellitus and genetically programmed defects in β-cell function,” Nature, vol. 414, no. 6865, pp. 788–791, 2001. View at Publisher · View at Google Scholar · View at Scopus
  9. A. S. Krolewski, M. Canessa, J. H. Warram et al., “Predisposition to hypertension and susceptibility to renal disease in insulin-dependent diabetes mellitus,” The New England Journal of Medicine, vol. 318, no. 3, pp. 140–145, 1988. View at Google Scholar · View at Scopus
  10. J. Eriksson, A. Franssila-Kallunki, A. Ekstrand et al., “Early metabolic defects in persons at increased risk for non-insulin-dependent diabetes mellitus,” The New England Journal of Medicine, vol. 321, no. 6, pp. 337–343, 1989. View at Google Scholar · View at Scopus
  11. R. Tisch and H. McDevitt, “Insulin-dependent diabetes mellitus,” Cell, vol. 85, no. 3, pp. 291–297, 1996. View at Publisher · View at Google Scholar · View at Scopus
  12. Y. Chen, “Diagnosis of diabetes,” The New England Journal of Medicine, vol. 368, no. 2, pp. 192–193, 2013. View at Publisher · View at Google Scholar
  13. H. Morita and R. Nagai, “Retinopathy progression in type 2 diabetes,” The New England Journal of Medicine, vol. 363, no. 22, p. 2171, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. K. M. V. Narayan and M. B. Weber, “Clinical risk factors, DNA variants, and the development of type 2 diabetes,” The New England Journal of Medicine, vol. 360, no. 13, pp. 1360–1361, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. F. B. Hu, J. E. Manson, M. J. Stampfer et al., “Diet, lifestyle, and the risk of type 2 diabetes mellitus in women,” The New England Journal of Medicine, vol. 345, no. 11, pp. 790–797, 2001. View at Publisher · View at Google Scholar · View at Scopus
  16. P. Hossain, B. Kawar, and M. El Nahas, “Obesity and diabetes in the developing world—a growing challenge,” The New England Journal of Medicine, vol. 356, no. 3, pp. 213–215, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. M. I. McCarthy, “Genomics, type 2 diabetes, and obesity,” The New England Journal of Medicine, vol. 363, no. 24, pp. 2339–2350, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. A. Tirosh, I. Shai, A. Afek et al., “Adolescent BMI trajectory and risk of diabetes versus coronary disease,” The New England Journal of Medicine, vol. 364, no. 14, pp. 1315–1325, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. R. G. Dluhy and G. T. McMahon, “Intensive glycemic control in the ACCORD and ADVANCE trials,” The New England Journal of Medicine, vol. 358, no. 24, pp. 2630–2633, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. A. Mitrakou, D. Kelley, M. Mokan et al., “Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance,” The New England Journal of Medicine, vol. 326, no. 1, pp. 22–29, 1992. View at Google Scholar · View at Scopus
  21. S. Dinneen, J. Gerich, and R. Rizza, “Carbohydrate metabolism in non-insulin-dependent diabetes mellitus,” The New England Journal of Medicine, vol. 327, no. 10, pp. 707–713, 1992. View at Google Scholar · View at Scopus
  22. F. Halperin, J. R. Ingelfinger, and G. T. McMahon, “Clinical decisions. Management of type 2 diabetes—polling results,” The New England Journal of Medicine, vol. 358, no. 7, article e8, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. E. R. Pearson, I. Flechtner, P. R. Njølstad et al., “Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations,” The New England Journal of Medicine, vol. 355, no. 5, pp. 467–477, 2006. View at Publisher · View at Google Scholar · View at Scopus
  24. A. J. Scheen and R. P. Radermecker, “Addition of incretin therapy to metformin in type 2 diabetes,” The Lancet, vol. 375, no. 9724, pp. 1410–1412, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. D. M. Nathan, “Thiazolidinediones for initial treatment of type 2 diabetes?” The New England Journal of Medicine, vol. 355, no. 23, pp. 2477–2480, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. J.-L. Chiasson, R. G. Josse, R. Gomis, M. Hanefeld, A. Karasik, and M. Laakso, “Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial,” The Lancet, vol. 359, no. 9323, pp. 2072–2077, 2002. View at Publisher · View at Google Scholar · View at Scopus
  27. A. B. Goldfine, “Assessing the cardiovascular safety of diabetes therapies,” The New England Journal of Medicine, vol. 359, no. 11, pp. 1092–1095, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. B. M. Psaty and C. D. Furberg, “The record on rosiglitazone and the risk of myocardial infarction,” The New England Journal of Medicine, vol. 357, no. 1, pp. 67–69, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. W. R. Hiatt, S. Kaul, and R. J. Smith, “The cardiovascular safety of diabetes drugs—insights from the rosiglitazone experience,” The New England Journal of Medicine, vol. 369, no. 14, pp. 1285–1287, 2013. View at Publisher · View at Google Scholar
  30. M. A. Nauck and J. J. Meier, “Individualised incretin-based treatment for type 2 diabetes,” The Lancet, vol. 376, no. 9739, pp. 393–394, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. D. J. Drucker, “The biology of incretin hormones,” Cell Metabolism, vol. 3, no. 3, pp. 153–165, 2006. View at Publisher · View at Google Scholar · View at Scopus
  32. C. Shaffer, “Incretin mimetics vie for slice of type 2 diabetes market,” Nature Biotechnology, vol. 25, no. 3, p. 263, 2007. View at Publisher · View at Google Scholar · View at Scopus
  33. J. A. Lovshin and D. J. Drucker, “Incretin-based therapies for type 2 diabetes mellitus,” Nature Reviews Endocrinology, vol. 5, no. 5, pp. 262–269, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. S. Madsbad, “Treatment of type 2 diabetes with incretin-based therapies,” The Lancet, vol. 373, no. 9662, pp. 438–439, 2009. View at Publisher · View at Google Scholar · View at Scopus
  35. B. Kreymann, G. Williams, M. A. Ghatei, and S. R. Bloom, “Glucagon-like peptide-1 7-36: a physiological incretin in man,” The Lancet, vol. 2, no. 8571, pp. 1300–1304, 1987. View at Google Scholar · View at Scopus
  36. A. Hirasawa, K. Tsumaya, T. Awaji et al., “Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120,” Nature Medicine, vol. 11, no. 1, pp. 90–94, 2005. View at Publisher · View at Google Scholar · View at Scopus
  37. B. Thorens, “Expression cloning of the pancreatic β cell receptor for the gluco-incretin hormone glucagon-like peptide 1,” Proceedings of the National Academy of Sciences of the United States of America, vol. 89, no. 18, pp. 8641–8645, 1992. View at Google Scholar · View at Scopus
  38. C. Parthier, M. Kleinschmidt, P. Neumann et al., “Crystal structure of the incretin-bound extracellular domain of a G protein-coupled receptor,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 35, pp. 13942–13947, 2007. View at Publisher · View at Google Scholar · View at Scopus
  39. M. Gutniak, C. Orskov, J. J. Holst, B. Ahren, and S. Efendic, “Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus,” The New England Journal of Medicine, vol. 326, no. 20, pp. 1316–1322, 1992. View at Google Scholar · View at Scopus
  40. L. A. Scrocchi, T. J. Brown, N. MacLusky et al., “Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene,” Nature Medicine, vol. 2, no. 11, pp. 1254–1258, 1996. View at Publisher · View at Google Scholar · View at Scopus
  41. J. J. Meier and M. A. Nauck, “Is secretion of glucagon-like peptide-1 reduced in type 2 diabetes mellitus?” Nature Clinical Practice Endocrinology and Metabolism, vol. 4, no. 11, pp. 606–607, 2008. View at Publisher · View at Google Scholar · View at Scopus
  42. H. Sell, M. Bluher, N. Kloting et al., “Adipose dipeptidyl peptidase-4 and obesity: correlation with insulin resistance and depot-specific release from adipose tissue in vivo and in vitro,” Diabetes Care, vol. 36, no. 12, pp. 4083–4090, 2013. View at Publisher · View at Google Scholar
  43. I. Chou, W. D. Lin, C. H. Wang et al., “Möbius syndrome in a male with XX/XY mosaicism,” BioMedicine, vol. 3, no. 2, pp. 102–104, 2013. View at Publisher · View at Google Scholar
  44. C.-H. Wang, W.-D. Lin, and F.-J. Tsai, “Craniofacial dysmorphism, what is your diagnosis?” BioMedicine, vol. 2, no. 2, pp. 49–50, 2012. View at Publisher · View at Google Scholar · View at Scopus
  45. D.-Y. Lin, F.-J. Tsai, C.-H. Tsai, and C.-Y. Huang, “Mechanisms governing the protective effect of 17β-estradiol and estrogen receptors against cardiomyocyte injury,” BioMedicine, vol. 1, no. 1, pp. 21–28, 2011. View at Publisher · View at Google Scholar · View at Scopus
  46. F. J. Tsai, “Rare diseases: a mysterious puzzle,” BioMedicine, vol. 3, no. 2, p. 65, 2013. View at Publisher · View at Google Scholar
  47. I. Chou, W. D. Lin, C. H. Wang et al., “Association analysis between Tourette's syndrome and two dopamine genes (DAT1, DBH) in Taiwanese children,” BioMedicine, vol. 3, no. 2, pp. 88–91, 2013. View at Publisher · View at Google Scholar
  48. C. H. Wang, W. D. Lin, D. T. Bau et al., “Appearance of acanthosis nigricans may precede obesity: an involvement of the insulin/IGF receptor signaling pathway,” BioMedicine, vol. 3, no. 2, pp. 82–87, 2013. View at Publisher · View at Google Scholar
  49. Y. T. Chang, W. D. Lin, Z. N. Chin et al., “Nonketotic hyperglycinemia: a case report and brief review,” BioMedicine, vol. 2, no. 2, pp. 80–82, 2012. View at Publisher · View at Google Scholar
  50. Y. M. Chang, B. K. Velmurugan, W. W. Kuo et al., “Inhibitory effect of alpinate Oxyphyllae fructus extracts on Ang II-induced cardiac pathological remodeling-related pathways in H9c2 cardiomyoblast cells,” BioMedicine, vol. 3, no. 4, pp. 148–152, 2013. View at Publisher · View at Google Scholar
  51. C. C. Lee, C. H. Tsai, L. Wan et al., “Increased incidence of Parkinsonism among Chinese with β-glucosidase mutation in central Taiwan,” BioMedicine, vol. 3, no. 2, pp. 92–94, 2013. View at Publisher · View at Google Scholar
  52. F.-J. Tsai, “Biomedicine brings the future nearer,” BioMedicine, vol. 1, no. 1, p. 1, 2011. View at Publisher · View at Google Scholar · View at Scopus
  53. W. Y. Lin, H. P. Liu, J. S. Chang et al., “Genetic variations within the PSORS1 region affect Kawasaki disease development and coronary artery aneurysm formation,” BioMedicine, vol. 3, no. 2, pp. 73–81, 2013. View at Publisher · View at Google Scholar
  54. W. L. Liao and F. J. Tsai, “Personalized medicine: a paradigm shift in healthcare,” BioMedicine, vol. 3, no. 2, pp. 66–72, 2013. View at Publisher · View at Google Scholar
  55. T.-Y. Tsai, K.-W. Chang, and C. Y.-C. Chen, “IScreen: world's first cloud-computing web server for virtual screening and de novo drug design based on TCM database@Taiwan,” Journal of Computer-Aided Molecular Design, vol. 25, no. 6, pp. 525–531, 2011. View at Publisher · View at Google Scholar · View at Scopus
  56. T.-T. Chang, M.-F. Sun, H.-Y. Chen et al., “Screening from the world's largest TCM database against H1N1 virus,” Journal of Biomolecular Structure and Dynamics, vol. 28, no. 5, pp. 773–786, 2011. View at Google Scholar · View at Scopus
  57. K. C. Chen, S. S. Chang, H. J. Huang, T. L. Lin, Y. J. Wu, and C. Y. Chen, “Three-in-one agonists for PPAR-alpha, PPAR-gamma, and PPAR-delta from traditional Chinese medicine,” Journal of Biomolecular Structure and Dynamics, vol. 30, no. 6, pp. 662–683, 2012. View at Publisher · View at Google Scholar
  58. K.-C. Chen, M.-F. Sun, S.-C. Yang et al., “Investigation into Potent Inflammation Inhibitors from Traditional Chinese Medicine,” Chemical Biology and Drug Design, vol. 78, no. 4, pp. 679–688, 2011. View at Publisher · View at Google Scholar · View at Scopus
  59. W. I. Tou, S. S. Chang, C. C. Lee, and C. Y. Chen, “Drug design for neuropathic pain regulation from traditional Chinese medicine,” Scientific Reports, vol. 3, article 844, 2013. View at Publisher · View at Google Scholar
  60. S.-C. Yang, S.-S. Chang, H.-Y. Chen, and C. Y.-C. Chen, “Identification of potent EGFR inhibitors from TCM Database@Taiwan,” PLoS Computational Biology, vol. 7, no. 10, Article ID e1002189, 2011. View at Publisher · View at Google Scholar · View at Scopus
  61. S.-S. Chang, H.-J. Huang, and C. Y.-C. Chen, “Two birds with one stone? Possible dual-targeting H1N1 inhibitors from traditional Chinese medicine,” PLoS Computational Biology, vol. 7, no. 12, Article ID e1002315, 2011. View at Publisher · View at Google Scholar · View at Scopus
  62. C. Y.-C. Chen, “TCM Database@Taiwan: the world's largest traditional Chinese medicine database for drug screening In Silico,” PLoS ONE, vol. 6, no. 1, Article ID e15939, 2011. View at Publisher · View at Google Scholar · View at Scopus
  63. C. A. Lipinski, “Lead- and drug-like compounds: the rule-of-five revolution,” Drug Discovery Today: Technologies, vol. 1, no. 4, pp. 337–341, 2004. View at Publisher · View at Google Scholar · View at Scopus
  64. C. Y.-C. Chen, “Weighted equation and rules—a novel concept for evaluating protein-ligand interaction,” Journal of Biomolecular Structure and Dynamics, vol. 27, no. 3, pp. 271–282, 2009. View at Google Scholar · View at Scopus
  65. C. Y. Chen, “A novel integrated framework and improved methodology of computer-aided drug design,” Current Topics in Medicinal Chemistry, vol. 13, no. 9, pp. 965–988, 2013. View at Publisher · View at Google Scholar
  66. W. I. Tou and C. Y. Chen, “May disordered protein cause serious drug side effect?” Drug Discovery Today, 2013. View at Publisher · View at Google Scholar
  67. C. Y. Chen and W. I. Tou, “How to design a drug for the disordered proteins?” Drug Discovery Today, vol. 18, no. 19-20, pp. 910–915, 2013. View at Google Scholar
  68. D. Van Der Spoel, E. Lindahl, B. Hess, G. Groenhof, A. E. Mark, and H. J. C. Berendsen, “GROMACS: fast, flexible, and free,” Journal of Computational Chemistry, vol. 26, no. 16, pp. 1701–1718, 2005. View at Publisher · View at Google Scholar · View at Scopus
  69. E. Chovancova, A. Pavelka, P. Benes et al., “CAVER 3.0: a tool for the analysis of transport pathways in dynamic protein structures,” PLoS Computational Biology, vol. 8, no. 10, Article ID e1002708, 2012. View at Publisher · View at Google Scholar